Dr Vibeke Wewer and colleagues evaluated the pattern of responsiveness of infliximab in children with Crohn's disease.
The research team also monitored the side effects of episodic administration of infliximab in children with Crohn's treated in Denmark from 1999 to 2003.
The team used the National Danish Crohn Colitis Database of infliximab.
All Danish Crohn's disease patients treated at pediatric departments with infliximab were identified using this database.
The clinical outcome was assessed by pattern recognition of the disease course 30 days after the first infliximab infusion, and 90 days after end of treatment.
Infliximab was given during a 3-year period to 24 Crohn's disease patients, of which 9 were male and 15 were female, with a median age of 15 years.
|71% of the children appeared to benefit from infliximab treatment
|Journal of Pediatric Gastroenterology & Nutrition|
The median disease duration of the patients was 26 months, and the patients received a median number of 6 infusions.
The researchers intravenously administered 5 milligrams of infliximab infusions per kilogram.
For immediate response, the team found that 8 patients achieved complete response, 10 partial response, and 6 had no response.
The researchers noted that 7 patients achieved prolonged response, defined as maintenance of complete long-term response or partial long-term response.
The team observed that 10 patients were infliximab dependent.
Dependency was defined as relapse of symptoms requiring reinfusions of infliximab to regain complete response or partial response.
The team found that 6 had no response, and a further 6 patients needed surgery during or after treatment with infliximab.
Side effects were observed in 4 patients, however no serious events were noted.
Dr Wewer's team concluded, “71% of the children appeared to benefit from infliximab treatment with minor side effects when given episodically.”
“Among these patients, 2 response patterns were recognized, including partial response after ending infliximab treatment, or dependency on reinfusions of infliximab.”